Alnylam Pharmaceuticals, Inc. ALNY, a leading RNAi therapeutics
company, announced today that it has presented new pre-clinical data from its
RNAi therapeutic program for the treatment of hemophilia and other bleeding
disorders at the 54^th American Society of Hematology Annual Meeting being
held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing
that ALN-AT3, a subcutaneously administered RNAi therapeutic targeting
antithrombin (AT), yields potent, dose-dependent, and durable knockdown of AT
in non-human primates (NHPs) with an up to four-fold increase in thrombin
generation. Alnylam's program in hemophilia comprises part of its ‘Alnylam
5x15' product strategy, by which the company aims to advance five programs in
clinical development, including programs in advanced stages, by the end of
2015.
In a poster titled “An RNAi Therapeutic Targeting Antithrombin Increases
Thrombin Generation in Nonhuman Primates,” (#3370) Alnylam scientists showed
that subcutaneous administration of ALN-AT3 in NHPs results in potent,
dose-dependent, and durable knockdown in serum AT, resulting in significant
increases in thrombin generation. Specifically, a single subcutaneous dose of
ALN-AT3 led to potent knockdown of serum AT, with an ED50 of 1 mg/kg. AT
suppression was durable, with effects lasting greater than six weeks after a
single dose. In addition, weekly subcutaneous doses of ALN-AT3 in NHPs led to
sustained AT knockdown of approximately 80% and greater than 90% at 0.5 mg/kg
and 1.5 mg/kg, respectively. These data enable an estimation of an ED50 dose
for weekly subcutaneous administration at 0.15-0.3 mg/kg at a volume of
injection for human administration expected to be less than 0.5 mL/injection.
Moreover, increased thrombin generation was closely correlated with AT
reduction, with an up to four-fold increase in peak thrombin at 90% AT
reduction. ALN-AT3 utilizes Alnylam's proprietary GalNAc-siRNA conjugate
delivery approach enabling subcutaneous dose administration with potential for
a once-weekly or twice-monthly dosing regimen. Alnylam expects to file an
investigational new drug (IND) application for ALN-AT3 in mid-2013.
In addition, results from Alnylam's ALN-AT3 program will be discussed at an
upcoming RNAi Roundtable on conjugate delivery that the company will host on
Friday, December 14 at 11:00 a.m. ET. The discussion will focus on progress
with the company's proprietary GalNAc-conjugate platform to deliver RNAi
therapeutics with subcutaneous dose administration. The roundtable will also
include a review of the company's two leading conjugate programs: ALN-TTRsc
for the treatment of transthyretin-mediated amyloidosis (ATTR) and ALN-AT3 for
the treatment of hemophilia and other bleeding disorders. The webinar will be
available live on the Capella section of the company's website,
www.alnylam.com/capella, and will also be available for replay on the Alnylam
website within 48 hours after the event.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in